[Use of Kovaltry® in patients with Hemophilia A: clinical and economical aspects from the pivotal clinical trials]

Lucia Sara D'Angiolella, Angelo Claudio Molinari, Paolo Angelo Cortesi, Antonio Coppola, Lorenzo Giovanni Mantovani

DOI: https://doi.org/10.7175/fe.v18i1.1284

Abstract

[Article in Italian]

Keywords

Hemophilia A; Recombinant factor VIII; Kovaltry

Full Text

HTML PDF

References

  • Barr RD, Saleh M, Furlong W, et al. Health status and health-related quality of life associated with hemophilia. Am J Hematol 2002; 71: 152-60; https://doi.org/10.1002/ajh.10191
  • Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10; https://doi.org/10.1111/j.1538-7836.2011.04214.x
  • Gringeri A, Leissinger C, Cortesi PA, et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia 2013; 19: 736-43; https://doi.org/10.1111/hae.12178
  • Valentino LA, Hakobyan N, Enockson, et al. Exploring the biological basis of haemophilic joint disease: experimental studies. Haemophilia 2012; 18: 310-8; https://doi.org/10.1111/j.1365-2516.2011.02669.x
  • Noone D, O’Mahony B, van Dijk JP, et al. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries. Haemophilia 2013; 19: 44-50; https://doi.org/10.1111/j.1365-2516.2012.02934.x
  • Ar MC, Baslar Z, Soysal T. Personalized prophylaxis in people with hemophilia A: challenges and achievements. Expert Rev Hematol 2016; 9: 1203-8; https://doi.org/10.1080/17474086.2016.1252670
  • Kodra Y, Cavazza M, Schieppati A, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus 2014; 12 Suppl 3: s567-75; https://doi.org/10.2450/2014.0042-14s
  • Rocino A, Cortesi PA, Scalone L, et al.; European Haemophilia Therapy Strategy Board (EHTSB). Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study). Haemophilia 2016; 22: 96-102; https://doi.org/10.1111/hae.12780
  • Abbonizio F, Giampaolo A, Coppola A, et al.; Italian Association of Haemophilia Centres. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy. Haemophilia 2014; 20: e243-50; https://doi.org/10.1111/hae.12456
  • Kavakli K, Yang R, Rusen L, et al. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost 2015; 13: 360-9; https://doi.org/10.1111/jth.12828
  • Saxena K, Lalezari S, Oldenburg J, et al. Efficacy and Safety of BAY 81-8973, a full length recombinant factor VIII: results from the LEOPOLD I. Haemophilia 2016; 22: 706-12; https://doi.org/10.1111/hae.12952
  • Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-25; https://doi.org/10.1182/blood-2013-10-529974
  • Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013; 19: 691-7; https://doi.org/10.1111/hae.12159
  • Ozelo M, Misgav M, Abdul Karim F, et al. Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®)) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial. Hemophilia 2015; 21: e436-9; https://doi.org/10.1111/hae.12737
  • Lentz SR, Cerqueira M, Janic D, et al. Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A. Haemophilia 2016; 22: e445-9; https://doi.org/10.1111/hae.12990
  • Tiede A, Oldenburg J, Lissitchkov T, et al. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A. Haemophilia 2016; 22: 374-80; https://doi.org/10.1111/hae.12859
  • Hermans C, Klamroth R, Richards M, et al. Outcome measures in European patients with haemophilia: Survey of implementation in routine clinical practice, perception of relevance and recommendations by European treaters in the EHTSB. Haemophilia 2016 [Epub ahead of print]; https://doi.org/10.1111/hae.13085

Statistics

Abstract: 2640 views
HTML: 1537 views
PDF: 493 views

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.